Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is th...
Saved in:
| Published in | mBio Vol. 11; no. 5 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
16.10.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2161-2129 2150-7511 2150-7511 |
| DOI | 10.1128/mBio.02590-20 |
Cover
Loading…
| Abstract | While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection.
In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms.
IMPORTANCE
While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection. |
|---|---|
| AbstractList | ABSTRACT In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms. IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection. In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms.IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection.In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms.IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection. While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection. In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms. IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection. While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection. In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms. In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of ≥1:160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptor-binding-domain (RBD)-specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms. While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection. |
| Author | Medjahed, Halima Lewin, Antoine Bazin, Renée Richard, Jonathan Perreault, Josée Gokool, Laurie Prévost, Jérémie Goyette, Guillaume Gasser, Romain Martel-Laferrière, Valérie Laumaea, Annemarie Morrisseau, Chantal Tremblay, Cécile Tremblay, Tony Finzi, Andrés Bégin, Philippe Kaufmann, Daniel E. Beaudoin-Bussières, Guillaume Anand, Sai Priya |
| Author_xml | – sequence: 1 givenname: Guillaume surname: Beaudoin-Bussières fullname: Beaudoin-Bussières, Guillaume organization: Centre de Recherche du CHUM, Quebec, Canada, Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada – sequence: 2 givenname: Annemarie surname: Laumaea fullname: Laumaea, Annemarie organization: Centre de Recherche du CHUM, Quebec, Canada, Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada – sequence: 3 givenname: Sai Priya surname: Anand fullname: Anand, Sai Priya organization: Centre de Recherche du CHUM, Quebec, Canada, Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada – sequence: 4 givenname: Jérémie surname: Prévost fullname: Prévost, Jérémie organization: Centre de Recherche du CHUM, Quebec, Canada, Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada – sequence: 5 givenname: Romain surname: Gasser fullname: Gasser, Romain organization: Centre de Recherche du CHUM, Quebec, Canada, Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada – sequence: 6 givenname: Guillaume surname: Goyette fullname: Goyette, Guillaume organization: Centre de Recherche du CHUM, Quebec, Canada – sequence: 7 givenname: Halima surname: Medjahed fullname: Medjahed, Halima organization: Centre de Recherche du CHUM, Quebec, Canada – sequence: 8 givenname: Josée surname: Perreault fullname: Perreault, Josée organization: Affaires Médicales et Innovation, Héma-Québec, Montreal, Quebec, Canada – sequence: 9 givenname: Tony surname: Tremblay fullname: Tremblay, Tony organization: Affaires Médicales et Innovation, Héma-Québec, Montreal, Quebec, Canada – sequence: 10 givenname: Antoine surname: Lewin fullname: Lewin, Antoine organization: Affaires Médicales et Innovation, Héma-Québec, Montreal, Quebec, Canada – sequence: 11 givenname: Laurie surname: Gokool fullname: Gokool, Laurie organization: Centre de Recherche du CHUM, Quebec, Canada – sequence: 12 givenname: Chantal surname: Morrisseau fullname: Morrisseau, Chantal organization: Centre de Recherche du CHUM, Quebec, Canada – sequence: 13 givenname: Philippe surname: Bégin fullname: Bégin, Philippe organization: Centre de Recherche du CHUM, Quebec, Canada, CHU Ste-Justine, Montreal, Quebec, Canada – sequence: 14 givenname: Cécile surname: Tremblay fullname: Tremblay, Cécile organization: Centre de Recherche du CHUM, Quebec, Canada, Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada – sequence: 15 givenname: Valérie surname: Martel-Laferrière fullname: Martel-Laferrière, Valérie organization: Centre de Recherche du CHUM, Quebec, Canada, Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada – sequence: 16 givenname: Daniel E. surname: Kaufmann fullname: Kaufmann, Daniel E. organization: Centre de Recherche du CHUM, Quebec, Canada, Département de Médecine, Université de Montréal, Montreal, Quebec, Canada – sequence: 17 givenname: Jonathan surname: Richard fullname: Richard, Jonathan organization: Centre de Recherche du CHUM, Quebec, Canada, Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada – sequence: 18 givenname: Renée surname: Bazin fullname: Bazin, Renée organization: Affaires Médicales et Innovation, Héma-Québec, Montreal, Quebec, Canada – sequence: 19 givenname: Andrés orcidid: 0000-0002-4992-5288 surname: Finzi fullname: Finzi, Andrés organization: Centre de Recherche du CHUM, Quebec, Canada, Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada, Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33067385$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkctP3DAQxi0EAgocuVY-9mLqZ2JfkOj2wUpICJb2anljezFN7CVOVup_X4eFqiB8GT---c2Mvw9gN6boADgl-IwQKj93X0I6w1QojCjeAYeUCIxqQcjutK8IooSqA3CS8wMuizEiGd4HB4zhqmZSHIKbr65pQ3QweXg5dqk3Lbx1eZ1idhmalQkxD3BxcbtAs_QLUbhYh98OhghnKW5M63Lj4gDn0YZNsKNp8zHY8yW4k-d4BH5-_3Y3u0RX1z_ms4sr1AiiBlQ69RzTJbZCGSasYorWSnlTcSMF80tBl4pxTsvRY6Eqy0qGkpbUQmLr2RGYb7k2mQe97kNn-j86maCfLlK_0qYfQtM67b3FzHvMOVbccWYsNY2kTlWuxtTawjrfstbjsnN2Gql8xCvo65cY7vUqbXQtKlUmKYBPz4A-PY4uD7oL5Wfa1kSXxqwpF0TyWtK6SD_-X-tfkRdPioBtBU2fcu6d100YzBDSVDq0mmA9ma8n8_WT-ZpOHaA3WS_g9_V_AYQgr28 |
| CitedBy_id | crossref_primary_10_1093_infdis_jiaa618 crossref_primary_10_3390_pathogens11121531 crossref_primary_10_1016_j_immuni_2021_03_023 crossref_primary_10_1039_D2SD00073C crossref_primary_10_1111_trf_16318 crossref_primary_10_1126_scitranslmed_abi7826 crossref_primary_10_1128_JCM_02511_20 crossref_primary_10_1128_JCM_00193_21 crossref_primary_10_1016_j_isci_2022_104528 crossref_primary_10_2196_25500 crossref_primary_10_3390_v12111214 crossref_primary_10_1126_science_abe8499 crossref_primary_10_3390_v15091926 crossref_primary_10_1128_mbio_00907_24 crossref_primary_10_3390_v14010144 crossref_primary_10_3390_ph15030365 crossref_primary_10_1016_j_celrep_2022_110368 crossref_primary_10_4103_ajprhc_ajprhc_4_23 crossref_primary_10_1016_j_chom_2020_11_001 crossref_primary_10_1016_j_immuni_2021_08_015 crossref_primary_10_1002_gch2_202100004 crossref_primary_10_1016_j_celrep_2021_108790 crossref_primary_10_1021_acsnano_1c03972 crossref_primary_10_3390_vaccines9020147 crossref_primary_10_1016_j_isci_2022_105904 crossref_primary_10_1002_jmv_70161 crossref_primary_10_3389_fimmu_2021_793142 crossref_primary_10_4103_jfmpc_jfmpc_1369_22 crossref_primary_10_1038_s41467_021_27649_y crossref_primary_10_12688_wellcomeopenres_19414_1 crossref_primary_10_1038_s41577_021_00550_x crossref_primary_10_1016_j_ijid_2021_01_061 crossref_primary_10_12688_wellcomeopenres_19414_2 crossref_primary_10_3389_fcimb_2022_988604 crossref_primary_10_7774_cevr_2022_11_1_96 crossref_primary_10_1016_j_bbrc_2020_11_026 crossref_primary_10_1016_j_ejim_2021_05_010 crossref_primary_10_1093_discim_kyac004 crossref_primary_10_1371_journal_ppat_1010569 crossref_primary_10_1016_j_intimp_2021_107622 crossref_primary_10_1016_j_xcrm_2021_100253 crossref_primary_10_1038_s41467_023_44265_0 crossref_primary_10_3390_microorganisms9122578 crossref_primary_10_1111_vox_13114 crossref_primary_10_1111_vox_13113 crossref_primary_10_1172_JCI145853 crossref_primary_10_1111_mec_15730 crossref_primary_10_1111_vox_13590 crossref_primary_10_3390_microorganisms9112259 crossref_primary_10_1016_j_jcvp_2021_100016 crossref_primary_10_1016_j_virol_2025_110512 crossref_primary_10_1099_jgv_0_001684 crossref_primary_10_1002_jmv_26863 crossref_primary_10_1016_j_celrep_2022_110429 crossref_primary_10_1038_s41586_021_03207_w crossref_primary_10_3389_fimmu_2022_1052424 crossref_primary_10_1002_jmv_27270 crossref_primary_10_1021_acs_jproteome_4c00586 crossref_primary_10_1016_j_jff_2021_104850 crossref_primary_10_1093_cid_ciaa1850 crossref_primary_10_3390_jcm9123847 crossref_primary_10_1093_clinchem_hvab069 crossref_primary_10_1016_j_jksus_2021_101366 crossref_primary_10_1016_j_virol_2021_09_001 crossref_primary_10_1038_s41598_021_83969_5 crossref_primary_10_1007_s11095_022_03323_w crossref_primary_10_2147_IJN_S427990 crossref_primary_10_3389_fimmu_2022_977064 crossref_primary_10_3390_v15061274 crossref_primary_10_3389_fimmu_2020_610300 crossref_primary_10_1093_infdis_jiac065 crossref_primary_10_1093_ofid_ofab220 crossref_primary_10_1016_j_xcrm_2023_100955 crossref_primary_10_1111_trf_16364 crossref_primary_10_1016_j_isci_2022_104990 crossref_primary_10_1080_21505594_2021_2019959 crossref_primary_10_1016_j_virol_2025_110467 crossref_primary_10_1093_ndt_gfac132 crossref_primary_10_1016_S2666_5247_22_00090_8 crossref_primary_10_1016_j_celrep_2022_111013 crossref_primary_10_1016_j_xcrm_2021_100290 crossref_primary_10_1371_journal_pone_0301367 crossref_primary_10_3389_fimmu_2023_1100594 crossref_primary_10_1038_s41564_020_00813_8 crossref_primary_10_3389_fnano_2022_1028186 crossref_primary_10_17269_s41997_022_00622_y crossref_primary_10_1038_s41467_021_21444_5 crossref_primary_10_1016_j_chom_2021_12_004 crossref_primary_10_1016_j_chom_2021_06_016 crossref_primary_10_1111_imr_13115 crossref_primary_10_1016_j_ekir_2024_04_072 crossref_primary_10_3390_v14112419 crossref_primary_10_1016_j_bios_2021_113165 crossref_primary_10_1038_s41564_021_00974_0 crossref_primary_10_3390_jcm9123989 crossref_primary_10_1126_sciadv_abj5629 crossref_primary_10_1371_journal_pone_0262868 crossref_primary_10_1016_j_ijid_2021_04_080 crossref_primary_10_1021_acs_jproteome_4c00285 crossref_primary_10_1016_j_vaccine_2022_01_040 crossref_primary_10_1515_cclm_2020_1347 crossref_primary_10_3389_fimmu_2020_610688 crossref_primary_10_3390_jcm13102965 crossref_primary_10_1080_19932820_2024_2348233 crossref_primary_10_1136_bmjopen_2021_054208 crossref_primary_10_1016_j_micres_2022_127145 crossref_primary_10_15212_ZOONOSES_2021_1003 crossref_primary_10_1111_trf_17037 crossref_primary_10_1016_j_isci_2022_105783 crossref_primary_10_3389_fimmu_2024_1505752 crossref_primary_10_3390_v14030532 crossref_primary_10_3389_fimmu_2022_796481 crossref_primary_10_1016_j_celrep_2023_111998 crossref_primary_10_1128_Spectrum_00886_21 crossref_primary_10_1182_blood_2020008367 crossref_primary_10_2169_internalmedicine_8019_21 crossref_primary_10_1016_j_tim_2024_01_005 crossref_primary_10_1016_j_isci_2021_102489 crossref_primary_10_3389_fimmu_2021_700429 crossref_primary_10_1186_s12879_021_06517_6 crossref_primary_10_1371_journal_pmed_1003868 crossref_primary_10_3389_fimmu_2023_1223936 crossref_primary_10_1016_j_intimp_2022_108767 crossref_primary_10_3390_v14010005 crossref_primary_10_1016_j_celrep_2022_111554 crossref_primary_10_3390_jcm10153305 crossref_primary_10_1016_j_ijid_2022_07_075 crossref_primary_10_1016_j_vaccine_2022_04_090 crossref_primary_10_1016_j_str_2023_11_015 crossref_primary_10_15252_embr_202153865 crossref_primary_10_3390_ijerph20043665 crossref_primary_10_1128_spectrum_01512_21 crossref_primary_10_3389_fimmu_2021_681586 crossref_primary_10_3389_fcimb_2021_791660 crossref_primary_10_1016_j_cell_2020_10_051 crossref_primary_10_3390_v16030342 crossref_primary_10_1016_j_jbc_2021_101151 crossref_primary_10_7759_cureus_40860 crossref_primary_10_1136_bmjopen_2021_051157 crossref_primary_10_1371_journal_pone_0272690 crossref_primary_10_1016_j_celrep_2021_110210 crossref_primary_10_3390_v14102178 crossref_primary_10_1016_j_chom_2021_06_001 crossref_primary_10_1038_s41467_022_33899_1 |
| Cites_doi | 10.1073/pnas.2004168117 10.1172/JCI138745 10.1001/jama.2020.10044 10.12688/wellcomeopenres.15927.1 10.1182/blood.2020008367 10.1084/jem.20201181 10.15585/mmwr.mm6923e4 10.1172/JCI140200 10.1101/2020.07.09.20148429 10.1016/j.xcrm.2020.100126 10.1093/cid/ciq106 10.1001/jama.2020.10218 10.1038/s41591-020-0965-6 10.3851/IMP3243 10.1038/s41586-020-2456-9 10.1056/NEJMoa2022483 10.1016/j.cell.2020.06.043 10.1007/s10096-004-1271-9 10.1101/2020.06.10.20126532 10.1172/JCI138003 10.1016/S1473-3099(20)30141-9 10.1126/science.abc5343 10.1101/2020.06.12.148726 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Beaudoin-Bussières et al. Copyright © 2020 Beaudoin-Bussières et al. 2020 Beaudoin-Bussières et al. |
| Copyright_xml | – notice: Copyright © 2020 Beaudoin-Bussières et al. – notice: Copyright © 2020 Beaudoin-Bussières et al. 2020 Beaudoin-Bussières et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1128/mBio.02590-20 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Antibodies against CoV-2 S in Convalescent Individuals |
| EISSN | 2150-7511 |
| ExternalDocumentID | oai_doaj_org_article_ffd03ff044094e43ad2ac82e96e702dd PMC7569150 33067385 10_1128_mBio_02590_20 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: CIHR grantid: 352417 – fundername: ; |
| GroupedDBID | --- 0R~ 53G 5VS AAFWJ AAGFI AAUOK AAYXX ADBBV AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW CITATION DIK E3Z EBS FRP GROUPED_DOAJ GX1 H13 HYE HZ~ KQ8 M48 O5R O5S O9- OK1 P2P PGMZT RHI RNS RPM RSF CGR CUY CVF ECM EIF M~E NPM RHF 7X8 5PM |
| ID | FETCH-LOGICAL-c519t-150f402b0d59a35d9392799fa64a853fb52b934424a8f0596d350f98d17580df3 |
| IEDL.DBID | M48 |
| ISSN | 2161-2129 2150-7511 |
| IngestDate | Wed Aug 27 01:28:19 EDT 2025 Thu Aug 21 18:28:43 EDT 2025 Fri Jul 11 11:07:57 EDT 2025 Wed Feb 19 02:30:25 EST 2025 Thu Apr 24 23:11:56 EDT 2025 Tue Jul 01 01:52:45 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | COVID-19 IgA SARS-CoV-2 RBD neutralization IgG coronavirus cross-reactivity IgM ELISA Spike glycoproteins convalescent plasma |
| Language | English |
| License | Copyright © 2020 Beaudoin-Bussières et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c519t-150f402b0d59a35d9392799fa64a853fb52b934424a8f0596d350f98d17580df3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Guillaume Beaudoin-Bussières, Annemarie Laumaea, Sai Priya Anand, Jérémie Prévost, and Romain Gasser contributed equally to this article. Author order was determined in order of increasing seniority of the project. |
| ORCID | 0000-0002-4992-5288 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1128/mBio.02590-20 |
| PMID | 33067385 |
| PQID | 2451847827 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ffd03ff044094e43ad2ac82e96e702dd pubmedcentral_primary_oai_pubmedcentral_nih_gov_7569150 proquest_miscellaneous_2451847827 pubmed_primary_33067385 crossref_citationtrail_10_1128_mBio_02590_20 crossref_primary_10_1128_mBio_02590_20 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20201016 |
| PublicationDateYYYYMMDD | 2020-10-16 |
| PublicationDate_xml | – month: 10 year: 2020 text: 20201016 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | mBio |
| PublicationTitleAlternate | mBio |
| PublicationYear | 2020 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_20_2 e_1_3_2_10_2 e_1_3_2_21_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_22_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_23_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_24_2 e_1_3_2_2_2 e_1_3_2_14_2 |
| References_xml | – ident: e_1_3_2_10_2 doi: 10.1073/pnas.2004168117 – ident: e_1_3_2_6_2 doi: 10.1172/JCI138745 – ident: e_1_3_2_11_2 doi: 10.1001/jama.2020.10044 – ident: e_1_3_2_16_2 doi: 10.12688/wellcomeopenres.15927.1 – ident: e_1_3_2_24_2 doi: 10.1182/blood.2020008367 – ident: e_1_3_2_19_2 doi: 10.1084/jem.20201181 – ident: e_1_3_2_22_2 doi: 10.15585/mmwr.mm6923e4 – ident: e_1_3_2_9_2 doi: 10.1172/JCI140200 – ident: e_1_3_2_21_2 doi: 10.1101/2020.07.09.20148429 – ident: e_1_3_2_15_2 doi: 10.1016/j.xcrm.2020.100126 – ident: e_1_3_2_4_2 doi: 10.1093/cid/ciq106 – ident: e_1_3_2_7_2 doi: 10.1001/jama.2020.10218 – ident: e_1_3_2_17_2 doi: 10.1038/s41591-020-0965-6 – ident: e_1_3_2_3_2 doi: 10.3851/IMP3243 – ident: e_1_3_2_12_2 doi: 10.1038/s41586-020-2456-9 – ident: e_1_3_2_20_2 doi: 10.1056/NEJMoa2022483 – ident: e_1_3_2_18_2 doi: 10.1016/j.cell.2020.06.043 – ident: e_1_3_2_5_2 doi: 10.1007/s10096-004-1271-9 – ident: e_1_3_2_14_2 doi: 10.1101/2020.06.10.20126532 – ident: e_1_3_2_8_2 doi: 10.1172/JCI138003 – ident: e_1_3_2_2_2 doi: 10.1016/S1473-3099(20)30141-9 – ident: e_1_3_2_13_2 doi: 10.1126/science.abc5343 – ident: e_1_3_2_23_2 doi: 10.1101/2020.06.12.148726 |
| SSID | ssj0000331830 |
| Score | 2.6007802 |
| Snippet | While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed.... In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to... ABSTRACT In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| SubjectTerms | Adult Aged Antibodies, Neutralizing - blood Antibodies, Viral - blood Betacoronavirus - immunology Convalescence coronavirus Coronavirus Infections - blood Coronavirus Infections - immunology COVID-19 Cross Reactions Editor's Pick ELISA Female Humans Immunity, Humoral Male Middle Aged Observation Pandemics Pneumonia, Viral - blood Pneumonia, Viral - immunology RBD SARS-CoV-2 Spike Glycoprotein, Coronavirus - chemistry Spike Glycoprotein, Coronavirus - immunology Spike glycoproteins Therapeutics and Prevention Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELUQUiUuqLR8pNDKlVBPNVj-iOMjbEEUCSRYQNwsJ7ZhRUlW7HLg33cm2V3tIiouPSZxFGtmknlPmXlDyK4ppbKm0iwBu2AKUhjzMXgWuBeV4DkvDTYKn53nJ9fq9Fbfzo36wpqwTh64M9x-SoHLlHAyslVRSR-ErwoRbR4NFyHg1xdy3hyZar_BEmOVT0U1RbH_eDho9iDBW85wtvdcEmq1-t8CmK_rJOcSz_FHsjpBjPSg2-kaWYr1J_KhmyH58plc_IrY3Rhpkyj4Bhvu6WVX-BpH1N8B8x-Naf_gss96zQ0TtD8cPEQ6qGmvqSHMOjkn-nvWmDVaJ9fHR1e9EzaZk8AqwF9jBpguAQ0sedDWSx0sYB5jbfK58pCNU6lFaaVSAg4TjtsJEu6wRQDoUPCQ5AZZrps6bhFqKlECwfOFzxP40HoFfEx7lReyCjqJjPycGs5VExFxnGXxx7VkQhQO7exaOzvBM_JjtnzYqWf8a-EhemG2CEWv2xMQCm4SCu69UMjI96kPHbwk-OfD17F5HjmhNDBZAEMmI5udT2ePkkiaZKEzYha8vbCXxSv14L4V4jY6t2D8L_9j89tkRSCVx2KZfIcsj5-e41fAO-PyWxvafwFc5P2l priority: 102 providerName: Directory of Open Access Journals |
| Title | Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33067385 https://www.proquest.com/docview/2451847827 https://pubmed.ncbi.nlm.nih.gov/PMC7569150 https://doaj.org/article/ffd03ff044094e43ad2ac82e96e702dd |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BEagXxJvwqIyEOOFi_IjjA0LtQilIRaLLor1ZTmyXiJKU3a1E_z3jJLt0q3LhslI2thLNN858X-KZAXiuSyGNrhSNqC6oxBBGXfCOeuZ4xVnOSp0ShQ8-5_sT-Wmqpn9LCg0GnF8q7VI_qcnsePv3r7O3uODf9Akwxaufu3W7jbHbMMT8KlzDoKTTGj0YmH73UBbJedmyyubFWZtwQyTyLFJP5XMBqqvjfxn5vLiH8lxQ2rsFNwc2SXZ6-G_DldDcget9f8mzu_DlXUiZj4G0kSBuKRmfHPabYsOcuCNXIzkk453DMR213ygn45P6RyB1Q0Ztgy7Yl3oiH1dJW_N7MNl7_3W0T4ceCrRCbragyPciSsSSeWWcUN4gH9LGRJdLh5E6loqXRkjJ8TCmVjxe4AxTeKQVBfNR3IeNpm3CQyC64iWKP1e4PCK-xknUasrJvBCVV5Fn8HJpOFsNBcZTn4tj2wkNXthkctuZ3HKWwYvV8JO-ssa_Bu4mFFaDUkHs7o92dmSH9WVj9EzEmBpoGxmkcJ67quDB5EEz7n0Gz5YYWlxA6auIa0J7OrdcKlS5SJR0Bg96TFeXWvpEBnoN7bV7WT_T1N-7It1a5QaN_-i_Zz6GTZ60fdo9kz-BjcXsNDxFArQot7oXB_j7Yfp6q3PzP8N0Bjw |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decline+of+Humoral+Responses+against+SARS-CoV-2+Spike+in+Convalescent+Individuals&rft.jtitle=mBio&rft.au=Beaudoin-Bussi%C3%A8res%2C+Guillaume&rft.au=Laumaea%2C+Annemarie&rft.au=Anand%2C+Sai+Priya&rft.au=Pr%C3%A9vost%2C+J%C3%A9r%C3%A9mie&rft.date=2020-10-16&rft.pub=American+Society+for+Microbiology&rft.eissn=2150-7511&rft.volume=11&rft.issue=5&rft_id=info:doi/10.1128%2FmBio.02590-20&rft_id=info%3Apmid%2F33067385&rft.externalDocID=PMC7569150 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2161-2129&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2161-2129&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2161-2129&client=summon |